Synlogic

[Available On-Demand]
Synlogic is bringing the transformational potential of synthetic biology to medicine. Synlogic’s pipeline includes Synthetic Biotic medicines for the treatment of Phenylketonuria (PKU), Enteric hyperoxaluria, and solid tumors. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as inflammatory and immune disorders.
Ticker:
SYBX
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
SYNB1618; SYNB8802
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Multiple
Speaker
photo
CEO and President
Synlogic